Alopecia Areata – Friday Pop Quiz – 01/12/2024
205122051220512
A 39-year-old woman with a history of alopecia areata presents for evaluation
of multiple macules and patches on her left mandibular face. She developed
these lesions slowly over several years, where they have remained stable for
many years. The patient’s goal now is to achieve repigmentation of the lesions.
The patient has previously used topical hydrocortisone 1% cream on the
lesions …
A 39-year-old woman with a history of alopecia areata presents for evaluation
of multiple macules and patches on her left mandibular face. She developed
these lesions slowly over several years, where they have remained stable for
many years. The patient’s goal now is to achieve repigmentation of the lesions.
The patient has previously used topical hydrocortisone 1% cream on the
lesions … Continue reading "Alopecia Areata – Friday Pop Quiz – 01/12/2024"
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium, interviewed Dr. Iltefat Hamzavi, a dermatologist with Henry Ford Health and associate professor of dermatology at Wayne State University School of Medicine. Learn from Dr. Hamzavi the key pillars of vitiligo treatment, and why there’s room to improve available options for melanocyte recruitment and repair. Dr. Hamza … 
Which of the following conditions is most associated with the findings in this 9-year-old boy?
A. Alopecia areata
B. Atopic dermatitis
C. Neurofibromatosis I
D. Parkinson disease
E. Tuberous sclerosis
To find out the correct answer and read the explanation, click here.
Brought to you by our brand partner
… 
Ruxolitinib (OPZELURA) is a twice daily topical cream that is FDA approved for non-segmental vitiligo and mild to moderate atopic dermatitis1. JAK inhibitors are a class of drugs effective in treating a wide variety of inflammatory conditions. Initially only FDA approved for non-dermatologic conditions such as rheumatoid arthritis and ulcerative colitis, there is now strong evidence that JAK/STAT … 
Next Steps in Derm, in partnership with Pigmentary Disorders Exchange Symposium interviewed Dr. Amit Pandya, staff dermatologist with Palo Alto Foundation Medical Group and adjunct professor in the department of dermatology at the University of Texas Southwestern Medical Center. Dr. Pandya says this is the most exciting time for him as a dermatologist with new vitiligo medications on the market an … 